PDGFRB e6::e11

CI-VAR-00004959Explore in graph →CIViC 5494

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like2
AGGF1::PDGFRB e6::e11	(oncogenic)	Oncogenic	C	Supports Oncogenicity	4	submitted	EID13007 A 4 yr old boy was diagnosed with precursor B-cell ALL. Patient had normal karyotype. The patient was refractory to prolonged induction therapy. Presence of PDGFRB rearrangement was indicated by F… (full text at CIViC) PMID 29434033 · Zhang et al., 2018 · Open in CIViC	civic
AGGF1::PDGFRB e6::e11	Imatinib	Predictive	C	Supports Sensitivity Response	4	submitted	EID13008 A 4 yr old boy with AGGF1::PDGFRB Fusion, and Ph-Like B-ALL was refractory to chemotherapy and did not respond to induction therapy. The patient was given imatinib, and within 8 weeks leukemia clearan… (full text at CIViC) PMID 29434033 · Zhang et al., 2018 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.